US 12,290,516 B2
Heterocyclic compounds as EphA4 inhibitors
Kit Yu Fu, Hong Kong (CN); Wing Yu Fu, Hong Kong (CN); Nancy Yuk-Yu Chu Ip, Hong Kong (CN); Shuo Gu, Zhejiang (CN); Xuhui Huang, Hong Kong (CN); and Chui Fun Fanny Ip, Hong Kong (CN)
Assigned to The Hong Kong University of Science and Technology, Kowloon (HK)
Appl. No. 16/612,698
Filed by The Hong Kong University of Science and Technology, Hong Kong (CN)
PCT Filed May 11, 2018, PCT No. PCT/IB2018/053315
§ 371(c)(1), (2) Date Nov. 11, 2019,
PCT Pub. No. WO2018/207154, PCT Pub. Date Nov. 15, 2018.
Claims priority of provisional application 62/505,332, filed on May 12, 2017.
Prior Publication US 2020/0206220 A1, Jul. 2, 2020
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 31/451 (2006.01); A61K 31/46 (2006.01); A61K 31/498 (2006.01); A61K 31/58 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/498 (2013.01) [A61K 9/0053 (2013.01); A61K 31/451 (2013.01); A61K 31/46 (2013.01); A61K 31/506 (2013.01); A61K 31/58 (2013.01); A61P 25/28 (2018.01)] 5 Claims
 
1. A method for treating a subject suffering from a spinal cord injury, comprising administering to the subject an effective amount of nilotinib.